Skip to main content
Top
Published in: International Ophthalmology 6/2014

01-12-2014 | Case Report

Significant reduction of diabetic macular edema following intravitreal ranibizumab injection in the fellow eye

Authors: Tryfon Rotsos, Chrysanthos Symeonidis, Ioanna Triantafillopoulou, Spyridon Kanellopoulos, Anastasios Kouris

Published in: International Ophthalmology | Issue 6/2014

Login to get access

Abstract

A significant therapeutic effect in the fellow eye after intravitreal ranibizumab injections was observed in a 39-year-old diabetic male. The patient was followed-up with fluorescein angiography (FA) and Optical Coherence Tomography (OCT). On referral, best-corrected visual acuity (BCVA) was 6/60 in the right eye and Counting Fingers in the left eye. FA revealed foveal leakage in both eyes. OCT revealed diabetic and cystoid macular edema (DME-CME) in both eyes. The patient was treated with two intravitreal ranibizumab injections in the left eye. BCVA was 6/15 and 6/30 one month after the last injection. OCT revealed significant improvement (DME elimination and significant CME improvement) in both eyes, despite the fact that only the left eye was treated. It is conceivable that, in this eye, chronic vascular damage was limited and a minimal quantity of ranibizumab had a positive effect on vascular permeability, resulting in DME resolution.
Literature
2.
go back to reference Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ (2007) Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114:2179–2182PubMedCrossRef Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ (2007) Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114:2179–2182PubMedCrossRef
3.
go back to reference Miki K, Miki A, Matsuoka M, Muramatsu D, Hackett SF, Campochiaro PA (2009) Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. Ophthalmology 116:1748–1754PubMedCentralPubMedCrossRef Miki K, Miki A, Matsuoka M, Muramatsu D, Hackett SF, Campochiaro PA (2009) Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. Ophthalmology 116:1748–1754PubMedCentralPubMedCrossRef
4.
go back to reference Matsuyama K, Ogata N, Matsuoka M, Wada M, Nishimura T, Takahashi K (2011) Effects of intravitreally injected bevacizumab on vascular endothelial growth factor in fellow eyes. J Ocul Pharmacol Ther 27:379–383PubMedCrossRef Matsuyama K, Ogata N, Matsuoka M, Wada M, Nishimura T, Takahashi K (2011) Effects of intravitreally injected bevacizumab on vascular endothelial growth factor in fellow eyes. J Ocul Pharmacol Ther 27:379–383PubMedCrossRef
5.
go back to reference Kim H, Robinson SB, Csaky KG (2009) FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis 15:2803–2812PubMedCentralPubMed Kim H, Robinson SB, Csaky KG (2009) FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis 15:2803–2812PubMedCentralPubMed
6.
go back to reference Xu L, Lu T, Tuomi L, Jumbe N, Lu J, Eppler S, Kuebler P, Damico-Beyer LA, Joshi A (2013) Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci 54:1616–1624PubMedCrossRef Xu L, Lu T, Tuomi L, Jumbe N, Lu J, Eppler S, Kuebler P, Damico-Beyer LA, Joshi A (2013) Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci 54:1616–1624PubMedCrossRef
7.
go back to reference Gamulescu MA, Helbig H (2010) Lack of therapeutic effect of ranibizumab in fellow eyes after intravitreal administration. J Ocul Pharmacol Ther 26:213–216PubMedCrossRef Gamulescu MA, Helbig H (2010) Lack of therapeutic effect of ranibizumab in fellow eyes after intravitreal administration. J Ocul Pharmacol Ther 26:213–216PubMedCrossRef
8.
go back to reference Barbazetto IA, Saroj N, Shapiro H, Wong P, Ho AC, Freund KB (2010) Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. Am J Ophthalmol 149:939–946PubMedCrossRef Barbazetto IA, Saroj N, Shapiro H, Wong P, Ho AC, Freund KB (2010) Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. Am J Ophthalmol 149:939–946PubMedCrossRef
9.
go back to reference Neri P, Mariotti C, Mercanti L, Salvolini S, Giovannini A (2008) Vitritis in the contralateral uninjected eye following intravitreal bevacizumab (Avastin). Int Ophthalmol 28:425–427PubMedCrossRef Neri P, Mariotti C, Mercanti L, Salvolini S, Giovannini A (2008) Vitritis in the contralateral uninjected eye following intravitreal bevacizumab (Avastin). Int Ophthalmol 28:425–427PubMedCrossRef
Metadata
Title
Significant reduction of diabetic macular edema following intravitreal ranibizumab injection in the fellow eye
Authors
Tryfon Rotsos
Chrysanthos Symeonidis
Ioanna Triantafillopoulou
Spyridon Kanellopoulos
Anastasios Kouris
Publication date
01-12-2014
Publisher
Springer Netherlands
Published in
International Ophthalmology / Issue 6/2014
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-014-9921-0

Other articles of this Issue 6/2014

International Ophthalmology 6/2014 Go to the issue